000304245 001__ 304245
000304245 005__ 20251031140910.0
000304245 0247_ $$2doi$$a10.1038/s41416-025-03164-5
000304245 0247_ $$2pmid$$apmid:40877636
000304245 0247_ $$2ISSN$$a0007-0920
000304245 0247_ $$2ISSN$$a1532-1827
000304245 0247_ $$2altmetric$$aaltmetric:180728267
000304245 037__ $$aDKFZ-2025-01799
000304245 041__ $$aEnglish
000304245 082__ $$a610
000304245 1001_ $$00000-0002-5470-4973$$aBallhausen, Alexej$$b0
000304245 245__ $$aPrimary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.
000304245 260__ $$aEdinburgh$$bNature Publ. Group$$c2025
000304245 3367_ $$2DRIVER$$aarticle
000304245 3367_ $$2DataCite$$aOutput Types/Journal article
000304245 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761916122_171916
000304245 3367_ $$2BibTeX$$aARTICLE
000304245 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304245 3367_ $$00$$2EndNote$$aJournal Article
000304245 500__ $$a2025 Nov;133(9):1297-1306
000304245 520__ $$aPatients with RAS wild-type (WT), left-sided metastatic colorectal cancer (mCRC), negatively hyperselected for anti-EGFR resistance alterations, benefit most from anti-EGFR-based first-line treatment. The predictive impact of these stratification parameters on maintenance strategy efficacy is unclear.This pooled analysis included individual patient data from the PanaMa (NCT01991873) and Valentino (NCT02476045) phase 2 trials. Patients with RAS WT mCRC received FOLFOX plus Panitumumab induction therapy followed by maintenance with 5-fluorouracil/leucovorin (5-FU/LV) plus Panitumumab vs. 5-FU/LV monotherapy (PanaMa) or Panitumumab monotherapy (Valentino). Outcomes included progression-free survival (PFS) and overall survival (OS). Subgroup analyses examined primary tumor sidedness (left vs. right) and hyperselection status (negative vs. altered).Among 607 patients receiving induction, sidedness and hyperselection status were available for 589 and 511 patients, respectively. Left-sided and negative hyperselected tumors were observed in 80.2% and 63.9% of patients, respectively. Panitumumab-based maintenance improved PFS in left-sided, negative hyperselected patients compared to 5-FU/LV alone, with no OS differences. PFS and OS were comparable for Panitumumab alone vs. Panitumumab plus 5-FU/LV.Tumor sidedness and hyperselection status significantly influence maintenance strategy efficacy in mCRC. For left-sided, negative hyperselected patients, Panitumumab monotherapy may optimize efficacy while minimizing toxicity. Further investigation into the relative contribution of individual hyperselection parameters in this setting is warranted.
000304245 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304245 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304245 7001_ $$aMorano, Federica$$b1
000304245 7001_ $$00000-0003-1041-0137$$aStahler, Arndt$$b2
000304245 7001_ $$00000-0002-7593-8138$$aLonardi, Sara$$b3
000304245 7001_ $$aKind, Andreas Jay$$b4
000304245 7001_ $$00000-0002-0520-4841$$aCremolini, Chiara$$b5
000304245 7001_ $$aSwoboda, Susanna$$b6
000304245 7001_ $$aRandon, Giovanni$$b7
000304245 7001_ $$00000-0003-4755-5743$$aHorst, David$$b8
000304245 7001_ $$aPrisciandaro, Michele$$b9
000304245 7001_ $$aAlig, Annabel Helga Sophie$$b10
000304245 7001_ $$aPircher, Chiara Carlotta$$b11
000304245 7001_ $$aJarosch, Armin$$b12
000304245 7001_ $$aAndena, Paola$$b13
000304245 7001_ $$00000-0002-4352-6788$$aKurreck, Annika$$b14
000304245 7001_ $$aChiaramonte, Anna Alessandra$$b15
000304245 7001_ $$00000-0002-3297-5801$$aStintzing, Sebastian$$b16
000304245 7001_ $$00000-0002-8530-8420$$aPietrantonio, Filippo$$b17
000304245 7001_ $$0P:(DE-HGF)0$$aModest, Dominik Paul$$b18
000304245 7001_ $$00000-0002-8999-2899$$aRaimondi, Alessandra$$b19
000304245 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-025-03164-5$$n9$$p1297-1306$$tBritish journal of cancer$$v133$$x0007-0920$$y2025
000304245 909CO $$ooai:inrepo02.dkfz.de:304245$$pVDB
000304245 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-3297-5801$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000304245 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000304245 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304245 9141_ $$y2025
000304245 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-19$$wger
000304245 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2022$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-19
000304245 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2022$$d2024-12-19
000304245 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK Koordinierungsstelle Berlin$$x0
000304245 980__ $$ajournal
000304245 980__ $$aVDB
000304245 980__ $$aI:(DE-He78)BE01-20160331
000304245 980__ $$aUNRESTRICTED